Derma Sciences Cmn (DSCI) 4.55 $DSCI Derma Scie
Post# of 273242
Posted On: 09/19/2016 9:06:50 AM
Derma Sciences Cmn (DSCI) 4.55 $DSCI
Derma Sciences Completes the Sale of Its First Aid Products Division
BusinessWire - Thu Sep 01, 3:05PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announces the completion of the sale of its First Aid Division (FAD) to Dukal Corporation for $12.4 million, including inventory. The proposed sale was first announced on July 27, 2016.
DSCI: 4.55 (-0.03)
Henry Schein Poised on Strategic Buyouts, Pricing Hurts
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:23AM CDT
On Sep 1, we issued an updated research report on Henry Schein, Inc. (HSIC).
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), HSIC: 164.10 (+1.33), MMSI: 24.14 (-0.29)
Others Overlooked Derma Sciences (DSCI), Should You Buy It Now?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:50AM CDT
Derma Sciences (DSCI) is well positioned for a solid gain, but has been overlooked by investors lately
DSCI: 4.55 (-0.03)
LabCorp's Takeover of Sequenom Wins Antitrust Clearance
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:26PM CDT
LabCorp (LH) recently got the antitrust review clearance for its previously announced acquisition of Sequenom.
DSCI: 4.55 (-0.03), SQNM: 2.39 (-0.01), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70)
Derma Sciences Receives Reimbursement Coding for New MEDIHONEY(R) Hydrogel Dressings
BusinessWire - Thu Aug 25, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the launch of new, MEDIHONEY(R) Hydrogel Sheet Dressings and the receipt of Healthcare Common Procedural Coding System (HCPCS) codes awarded on August 19, 2016 by the Centers for Medicare and Medicaid Services (CMS).
DSCI: 4.55 (-0.03)
Derma Sciences' AMNIOEXCEL(R) Now Eligible for Reimbursement by Medicare Administrative Contractor NGS
BusinessWire - Wed Aug 24, 3:05PM CDT
Derma Sciences, Inc. (NasdaqSCI), a tissue regeneration company focused on advanced wound and burn care, announces that National Government Services (NGS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Northeast and Midwest, and National MAC for Jurisdiction 6, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective September 1, 2016. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment.
DSCI: 4.55 (-0.03)
LabCorp Q2 Results Strong, Sequenom Buyout Raises Hope
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:16AM CDT
On Aug 18, 2016, we issued an updated research report on LabCorp (LH), a leading independent clinical laboratory company.
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70), ATRS: 1.43 (+0.03)
Derma Sciences Names Russell Olsen President of Advanced Wound Care
BusinessWire - Thu Aug 18, 6:30AM CDT
Derma Sciences, Inc. (NasdaqSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Mr. Olsen is President and Chief Executive Officer of BioD, LLC, a regenerative medicine products company Derma Sciences acquired earlier this month.
DSCI: 4.55 (-0.03)
New Strong Buy Stocks for August 11th
Tirthankar Chakraborty - Zacks Investment Research - Thu Aug 11, 6:17AM CDT
New Strong Buy Stocks for August 11th
DSCI: 4.55 (-0.03), DISCK: 23.61 (-0.09), DGI: 24.59 (-0.66), BEAT: 18.44 (-0.75), CVCY: 15.80 (+0.07)
Derma Sciences Reports 2016 Second Quarter Financial Results
BusinessWire - Tue Aug 09, 6:30AM CDT
--2016 financial guidance revised to include recent transactions
DSCI: 4.55 (-0.03)
Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 9th
BusinessWire - Wed Aug 03, 8:13AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on August 9, 2016 to discuss the financial results for the second quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.55 (-0.03)
Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced Wound Care and Regenerative Products
BusinessWire - Thu Jul 28, 6:30AM CDT
--Will add 235 independent sales representatives and seven direct sales representatives with no call-point or customer overlap
DSCI: 4.55 (-0.03)
Why Derma Sciences (DSCI) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:35AM CDT
Derma Sciences (DSCI) has a decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
DSCI: 4.55 (-0.03)
Can The Uptrend Continue for Derma Sciences (DSCI)?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:56AM CDT
Investors certainly have to be happy with Derma Sciences Inc (DSCI) and its short term performance
DSCI: 4.55 (-0.03)
Derma Sciences reports 1Q loss
Automated Insights - Wed May 11, 6:37AM CDT
PRINCETON, N.J. (AP) _ Derma Sciences Inc. (DSCI) on Wednesday reported a loss of $1.8 million in its first quarter.
DSCI: 4.55 (-0.03)
Derma Sciences Reports 2016 First Quarter Financial Results
BusinessWire - Wed May 11, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.55 (-0.03)
Research and Markets -- European Advanced Wound Care Market Analysis - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Shire, Organogenesis, Derma Sciences
PR Newswire Europe - Fri May 06, 2:11PM CDT
DUBLIN, May 6, 2016 /PRNewswire/ --
DSCI: 4.55 (-0.03)
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11th
BusinessWire - Fri May 06, 1:31PM CDT
Derma Sciences, Inc. (NasdaqSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.55 (-0.03)
Derma Sciences Announces AMNIOEXCEL(R) Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS
BusinessWire - Wed Apr 27, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Coverage is effective as of April 1, 2016. CGS is the sixth MAC to issue local coverage determinations for AMNIOEXCEL(R).
DSCI: 4.55 (-0.03)
Derma Sciences Completes the Sale of Its First Aid Products Division
BusinessWire - Thu Sep 01, 3:05PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announces the completion of the sale of its First Aid Division (FAD) to Dukal Corporation for $12.4 million, including inventory. The proposed sale was first announced on July 27, 2016. DSCI: 4.55 (-0.03)
Henry Schein Poised on Strategic Buyouts, Pricing Hurts
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:23AM CDT
On Sep 1, we issued an updated research report on Henry Schein, Inc. (HSIC).
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), HSIC: 164.10 (+1.33), MMSI: 24.14 (-0.29)
Others Overlooked Derma Sciences (DSCI), Should You Buy It Now?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:50AM CDT
Derma Sciences (DSCI) is well positioned for a solid gain, but has been overlooked by investors lately
DSCI: 4.55 (-0.03)
LabCorp's Takeover of Sequenom Wins Antitrust Clearance
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:26PM CDT
LabCorp (LH) recently got the antitrust review clearance for its previously announced acquisition of Sequenom.
DSCI: 4.55 (-0.03), SQNM: 2.39 (-0.01), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70)
Derma Sciences Receives Reimbursement Coding for New MEDIHONEY(R) Hydrogel Dressings
BusinessWire - Thu Aug 25, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the launch of new, MEDIHONEY(R) Hydrogel Sheet Dressings and the receipt of Healthcare Common Procedural Coding System (HCPCS) codes awarded on August 19, 2016 by the Centers for Medicare and Medicaid Services (CMS).
DSCI: 4.55 (-0.03)
Derma Sciences' AMNIOEXCEL(R) Now Eligible for Reimbursement by Medicare Administrative Contractor NGS
BusinessWire - Wed Aug 24, 3:05PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announces that National Government Services (NGS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Northeast and Midwest, and National MAC for Jurisdiction 6, has retired its local coverage determination (LCD) for cellular or tissue-based products (CTPs) effective September 1, 2016. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for coverage with appropriate documentation of medical necessity as a second-line therapy following standard wound care treatment. DSCI: 4.55 (-0.03)
LabCorp Q2 Results Strong, Sequenom Buyout Raises Hope
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:16AM CDT
On Aug 18, 2016, we issued an updated research report on LabCorp (LH), a leading independent clinical laboratory company.
DSCI: 4.55 (-0.03), ALGN: 93.84 (+0.91), LH: 135.38 (+0.70), ATRS: 1.43 (+0.03)
Derma Sciences Names Russell Olsen President of Advanced Wound Care
BusinessWire - Thu Aug 18, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Mr. Olsen is President and Chief Executive Officer of BioD, LLC, a regenerative medicine products company Derma Sciences acquired earlier this month. DSCI: 4.55 (-0.03)
New Strong Buy Stocks for August 11th
Tirthankar Chakraborty - Zacks Investment Research - Thu Aug 11, 6:17AM CDT
New Strong Buy Stocks for August 11th
DSCI: 4.55 (-0.03), DISCK: 23.61 (-0.09), DGI: 24.59 (-0.66), BEAT: 18.44 (-0.75), CVCY: 15.80 (+0.07)
Derma Sciences Reports 2016 Second Quarter Financial Results
BusinessWire - Tue Aug 09, 6:30AM CDT
--2016 financial guidance revised to include recent transactions
DSCI: 4.55 (-0.03)
Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 9th
BusinessWire - Wed Aug 03, 8:13AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on August 9, 2016 to discuss the financial results for the second quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
DSCI: 4.55 (-0.03)
Derma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced Wound Care and Regenerative Products
BusinessWire - Thu Jul 28, 6:30AM CDT
--Will add 235 independent sales representatives and seven direct sales representatives with no call-point or customer overlap
DSCI: 4.55 (-0.03)
Why Derma Sciences (DSCI) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:35AM CDT
Derma Sciences (DSCI) has a decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
DSCI: 4.55 (-0.03)
Can The Uptrend Continue for Derma Sciences (DSCI)?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:56AM CDT
Investors certainly have to be happy with Derma Sciences Inc (DSCI) and its short term performance
DSCI: 4.55 (-0.03)
Derma Sciences reports 1Q loss
Automated Insights - Wed May 11, 6:37AM CDT
PRINCETON, N.J. (AP) _ Derma Sciences Inc. (DSCI) on Wednesday reported a loss of $1.8 million in its first quarter.
DSCI: 4.55 (-0.03)
Derma Sciences Reports 2016 First Quarter Financial Results
BusinessWire - Wed May 11, 6:30AM CDT
--Conference call begins at 11:00 a.m. Eastern Time today
DSCI: 4.55 (-0.03)
Research and Markets -- European Advanced Wound Care Market Analysis - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Shire, Organogenesis, Derma Sciences
PR Newswire Europe - Fri May 06, 2:11PM CDT
DUBLIN, May 6, 2016 /PRNewswire/ --
DSCI: 4.55 (-0.03)
Derma Sciences to Hold First Quarter Financial Results Conference Call on May 11th
BusinessWire - Fri May 06, 1:31PM CDT
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones. DSCI: 4.55 (-0.03)
Derma Sciences Announces AMNIOEXCEL(R) Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGS
BusinessWire - Wed Apr 27, 6:30AM CDT
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the Company's AMNIOEXCEL(R) Amniotic Allograft Membrane (AMNIOEXCEL(R)) will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Coverage is effective as of April 1, 2016. CGS is the sixth MAC to issue local coverage determinations for AMNIOEXCEL(R).
DSCI: 4.55 (-0.03)
(0)
(0)Scroll down for more posts ▼